Watch the Spotlight on Immuno-Oncology Conference On Demand

Already registered for #IO23ASGCT? Access the conference here.

Welcome to our inaugural Spotlight on Immuno-Oncology Conference! If you haven't registered yet, here's why you should.

An Evolving Field

We're going beyond the basics of cell therapy and CAR T to discover new approaches to immunotherapy. Immediate Past President Hans-Peter Kiem, MD, PhD, spoke to Immuno-Oncology Insights about his motivation for launching this IO-focused meeting.

"Many of our ASGCT members have spent their careers in this field performing the underlying research and developing the gene therapy and gene editing tools that have led to the development of these transformative immunotherapies for cancer," Dr. Kiem said. "There are now several approved therapies, with many more to come. The field of immunotherapy has evolved from the use of unmodified T cells, with genetically modified T cells now being developed for most indications and cancers—and this new field of synthetic biology and immunology will only continue to grow and evolve."

Read the full article

Top-Tier Speakers 

You'll hear from these experts and more!

Catherine Bollard, MD The George Washington University Native T-Cells for Adoptive Cell Therapy	Chiara Bonini, MD Vita-Salute San Raffaele University TCR and Inhibitory Receptor Genome Editing
Paula Cannon, PhD University of Southern California Engineering B cells to express fully customizable antibodies	Michel Sadelain, MD, PhD Memorial Sloan Kettering Cancer Center AG Sensitivity and T Cell Persistence

View the agenda

Innovative Research

Browse the latest science on cancer immunotherapy, B cell malignancies, genome and epigenome editing, and more, to get ready for the conference. Then see it presented live next month!

To help you navigate the collection, the Program Committee has chosen six abstracts to represent the top research in each category. 

B Cell Malignancies & Beyond

High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Tuesday, August 1 | 11:55 AM - 12:10 PM

Novel CAR Designs and Approaches

Microbial Metabolites Guide the Engineering and Epigenetic-Metabolic Reprogramming of CAR T Cells for the Treatment of Solid Tumors

Tuesday, August 1 | 2:40 PM - 2:55 PM

TCR-Based Cancer Immunotherapy

Identification of Peptides Derived from Alternative Splicing for TCR-T Cell Therapies and Cancer Vaccines

Tuesday, August 1 | 4:45 PM - 5:00 PM

Direct In Vivo Delivery

Targeted in Vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform

Wednesday, August 2 | 9:40 AM - 9:55 AM

Genome & Epigenome Editing for Cancer Immunotherapy

CD47 Enhances CAR T Survival in NSG Recipients and Allogeneic Mice

Wednesday, August 2 | 11:45 AM - 12:00 PM

Beyond T-Cells

CD70 Knockout Provides Increased NK Cell Proliferation In Vivo

Wednesday, August 2 | 11:45 AM - 12:00 PM

Browse the abstracts collection

We hope to see you in Seattle or virtually in August!

Register now

Related Articles